# IGNYTE (NCT03767348)

> Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03767348
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Replimune, Inc.
- Conditions: Non-Small Cell Lung Cancer (NSCLC); Microsatellite Instability-High (MSI-H); Non-melanoma Skin Cancer (NMSC); Cutaneous Melanoma
- Interventions: RP1; nivolumab
- Enrollment: 340
- Primary outcome: Percentage of adverse events (AEs)
- Primary outcome: Percentage of serious adverse events (SAEs)
- Primary outcome: Percentage of dose limiting toxicities (DLTs)
- Primary outcome: Percentage of overall response rate (ORR)
- Primary outcome: Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1

## Commentary we found

- X threads: 10
- YouTube: 6
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ignyte-nct03767348

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03767348", "email": "<work email>"}; the inbox owner confirms by the emailed link.